PTC THERAPEUTICS, INC. (NASDAQ:PTCT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
PTC THERAPEUTICS, INC. (NASDAQ:PTCT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On April 11, 2017, Mr. Ronald Renaud, a member of the board of directors (the “Board”) of PTC Therapeutics, Inc. (the “Company”), notified the Company that he will not stand for re-election when his term expires at the Company’s 2017 annual meeting of stockholders (the “2017 Annual Meeting”). Mr. Renaud is expected to continue his service on the Board until the 2017 Annual Meeting.
Mr. Renaud has informed the Company that his decision is driven by a need to reduce the number of his outside public company board commitments as a result of his obligations as chief executive officer to an early-stage biopharmaceutical company and was not due to any disagreement with the Company.
About PTC THERAPEUTICS, INC. (NASDAQ:PTCT)
PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) in collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596). It has two compounds in clinical development within the SMA program: RG7800 and RG7916. PTC THERAPEUTICS, INC. (NASDAQ:PTCT) Recent Trading Information
PTC THERAPEUTICS, INC. (NASDAQ:PTCT) closed its last trading session up +0.30 at 10.68 with 1,018,232 shares trading hands.
PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) in collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596). It has two compounds in clinical development within the SMA program: RG7800 and RG7916. PTC THERAPEUTICS, INC. (NASDAQ:PTCT) Recent Trading Information
PTC THERAPEUTICS, INC. (NASDAQ:PTCT) closed its last trading session up +0.30 at 10.68 with 1,018,232 shares trading hands.